Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome

Overview

Journal Metabolites

Publisher MDPI

Date 2022 Aug 25

PMID 36005598

Authors

Aiperi K Khasanova

Vera S Dobrodeeva

Natalia A Shnayder

Marina M Petrova

Elena A Pronina

Elena N Bochanova

Natalia V Lareva

Natalia P Garganeeva

Daria A Smirnova

Regina F Nasyrova

Affiliations

Soon will be listed here.

Abstract

Metabolic syndrome (MetS) is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Antipsychotic (AP)-induced MetS (AIMetS) is the most common adverse drug reaction (ADR) of psychiatric pharmacotherapy. Herein, we review the results of studies of blood (serum and plasma) and urinary biomarkers as predictors of AIMetS in patients with schizophrenia (Sch). We reviewed 1440 studies examining 38 blood and 19 urinary metabolic biomarkers, including urinary indicators involved in the development of AIMetS. Among the results, only positive associations were revealed. However, at present, it should be recognized that there is no consensus on the role of any particular urinary biomarker of AIMetS. Evaluation of urinary biomarkers of the development of MetS and AIMetS, as one of the most common concomitant pathological conditions in the treatment of patients with psychiatric disorders, may provide a key to the development of strategies for personalized prevention and treatment of the condition, which is considered a complication of AP therapy for Sch in clinical practice.

Citing Articles

Prevalence of metabolic syndrome and its components according to altitude levels: a systematic review and meta-analysis.

Zila-Velasque J, Grados-Espinoza P, Challapa-Mamani M, Sanchez-Alcantara F, Cedillo-Balcazar J, Cs A Sci Rep. 2024; 14(1):27581.

PMID: 39528530 PMC: 11555074. DOI: 10.1038/s41598-024-77928-z.

Validity of handgrip strength for assessing cognition and psychotic symptoms in hospitalized patients with stable schizophrenia.

Pu J, Wang B, Wang Y PLoS One. 2024; 19(9):e0308133.

PMID: 39325780 PMC: 11426447. DOI: 10.1371/journal.pone.0308133.

Gut microbiome and metabolism alterations in schizophrenia with metabolic syndrome severity.

Zhao H, Zhu G, Zhu T, Ding B, Xu A, Gao S BMC Psychiatry. 2024; 24(1):529.

PMID: 39048972 PMC: 11267952. DOI: 10.1186/s12888-024-05969-9.

Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model.

Horska K, Skrede S, Kucera J, Kuzminova G, Suchy P, Micale V CNS Neurosci Ther. 2024; 30(2):e14565.

PMID: 38421095 PMC: 10850806. DOI: 10.1111/cns.14565.

Influence of antipsychotic medications on hyperlipidemia risk in patients with schizophrenia: evidence from a population-based cohort study and hepatic lipid homeostasis gene expression.

Wu T, Tien N, Lin C, Cheah Y, Hsu C, Tsai F Front Med (Lausanne). 2023; 10:1137977.

PMID: 37425327 PMC: 10324036. DOI: 10.3389/fmed.2023.1137977.

References

Cameron N, EATON S, Cotter M, Tesfaye S . Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001; 44(11):1973-88. DOI: 10.1007/s001250100001. View

Hopps E, Noto D, Caimi G, Averna M . A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis. 2009; 20(1):72-7. DOI: 10.1016/j.numecd.2009.06.002. View

Bouvier M, Fehsel K, Schmitt A, Meisenzahl-Lechner E, Gaebel W, von Wilmsdorff M . Sex-dependent effects of long-term clozapine or haloperidol medication on red blood cells and liver iron metabolism in Sprague Dawley rats as a model of metabolic syndrome. BMC Pharmacol Toxicol. 2022; 23(1):8. PMC: 8760835. DOI: 10.1186/s40360-021-00544-4. View

Lin C, Huang P, Wu C, Sung F, Su T . Association between urine lead levels and cardiovascular disease risk factors, carotid intima-media thickness and metabolic syndrome in adolescents and young adults. Int J Hyg Environ Health. 2019; 223(1):248-255. DOI: 10.1016/j.ijheh.2019.08.005. View

Saha S, Chant D, McGrath J . A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch Gen Psychiatry. 2007; 64(10):1123-31. DOI: 10.1001/archpsyc.64.10.1123. View

Wu J, Tomsa D, Zhang M, Komenda P, Tangri N, Rigatto C . A Passive Mixing Microfluidic Urinary Albumin Chip for Chronic Kidney Disease Assessment. ACS Sens. 2018; 3(10):2191-2197. DOI: 10.1021/acssensors.8b01072. View

Devaraj S, Xu D, Jialal I . C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation. 2003; 107(3):398-404. DOI: 10.1161/01.cir.0000052617.91920.fd. View

Al-Hamodi Z, Ismail I, Saif-Ali R, Ahmed K, Muniandy S . Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects. Cardiovasc Diabetol. 2011; 10:23. PMC: 3064636. DOI: 10.1186/1475-2840-10-23. View

Milner K, van der Poorten D, Xu A, Bugianesi E, Kench J, Lam K . Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology. 2009; 49(6):1926-34. DOI: 10.1002/hep.22896. View

10.

Newsome C, Shiell A, Fall C, Phillips D, Shier R, Law C . Is birth weight related to later glucose and insulin metabolism?--A systematic review. Diabet Med. 2003; 20(5):339-48. DOI: 10.1046/j.1464-5491.2003.00871.x. View

11.

Leiva E, Mujica V, Sepulveda P, Guzman L, Nunez S, Orrego R . High levels of iron status and oxidative stress in patients with metabolic syndrome. Biol Trace Elem Res. 2012; 151(1):1-8. DOI: 10.1007/s12011-012-9525-3. View

12.

Yin Q, Chen X, Li L, Zhou R, Huang J, Yang D . Apolipoprotein B/apolipoprotein A1 ratio is a good predictive marker of metabolic syndrome and pre-metabolic syndrome in Chinese adolescent women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2012; 39(1):203-9. DOI: 10.1111/j.1447-0756.2012.01907.x. View

13.

Boyraz M, Cekmez F, Karaoglu A, Cinaz P, Durak M, Bideci A . Relationship of adipokines (adiponectin, resistin and RBP4) with metabolic syndrome components in pubertal obese children. Biomark Med. 2013; 7(3):423-8. DOI: 10.2217/bmm.13.14. View

14.

Turk V, Bode W . The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 1991; 285(2):213-9. DOI: 10.1016/0014-5793(91)80804-c. View

15.

Hotamisligil G . Inflammation and metabolic disorders. Nature. 2006; 444(7121):860-7. DOI: 10.1038/nature05485. View

16.

van Winkel R, Rutten B, Peerbooms O, Peuskens J, van Os J, De Hert M . MTHFR and risk of metabolic syndrome in patients with schizophrenia. Schizophr Res. 2010; 121(1-3):193-8. DOI: 10.1016/j.schres.2010.05.030. View

17.

Naveed B, Weiden M, Kwon S, Gracely E, Comfort A, Ferrier N . Metabolic syndrome biomarkers predict lung function impairment: a nested case-control study. Am J Respir Crit Care Med. 2011; 185(4):392-9. PMC: 3297095. DOI: 10.1164/rccm.201109-1672OC. View

18.

Mateo-Gallego R, Calmarza P, Jarauta E, Burillo E, Cenarro A, Civeira F . Serum ferritin is a major determinant of lipid phenotype in familial combined hyperlipidemia and familial hypertriglyceridemia. Metabolism. 2009; 59(2):154-8. DOI: 10.1016/j.metabol.2009.06.021. View

19.

Lang R, Dieminger N, Beusch A, Lee Y, Dunkel A, Suess B . Bioappearance and pharmacokinetics of bioactives upon coffee consumption. Anal Bioanal Chem. 2013; 405(26):8487-503. DOI: 10.1007/s00216-013-7288-0. View

20.

Soukup M, Biesiada I, Henderson A, Idowu B, Rodeback D, Ridpath L . Salivary uric acid as a noninvasive biomarker of metabolic syndrome. Diabetol Metab Syndr. 2012; 4(1):14. PMC: 3428646. DOI: 10.1186/1758-5996-4-14. View